DiPT

Last updated

DiPT
DiPT.svg
DiPT-3d-sticks.png
Clinical data
Pronunciation /ˌdˌsˌprpɪlˈtrɪptəmn/
Other namesDiisopropyltryptamine; N,N-Diisopropyltryptamine; DiPT; DIPT; Dipt; Dipsy
Routes of
administration
Oral, smoking [1] [2] [3] [4] [5]
Drug class Serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Legal status
Legal status
  • AU:Unscheduled
  • CA:Unscheduled
  • DE: NpSG (Industrial and scientific use only)
  • UK: Class A
  • US:Unscheduled
  • UN:Unscheduled
Pharmacokinetic data
Onset of action Oral: 20 minutes–1 hour [1] [2] [3]
Smoking: 4–8 minutes [1]
Duration of action 4–8 hours [1] [2] [3]
Identifiers
  • 3-[2-(Diisopropylamino)ethyl]indole
CAS Number
PubChem CID
ChemSpider
UNII
ChEBI
CompTox Dashboard (EPA)
Chemical and physical data
Formula C16H24N2
Molar mass 244.382 g·mol−1
3D model (JSmol)
  • CC(C)N(CCc1c[nH]c2ccccc12)C(C)C
  • InChI=1S/C16H24N2/c1-12(2)18(13(3)4)10-9-14-11-17-16-8-6-5-7-15(14)16/h5-8,11-13,17H,9-10H2,1-4H3 Yes check.svgY
  • Key:ZRVAAGAZUWXRIP-UHFFFAOYSA-N Yes check.svgY
   (verify)

Diisopropyltryptamine (DiPT), also known as N,N-diisopropyltryptamine, is a psychedelic drug of the tryptamine family related to dimethyltryptamine (DMT). [6] [1] [2] [3] It is unusual among psychedelics in that at usual doses it primarily or exclusively produces strong auditory changes, including decreased pitch, harmonic distortion, and sound unfamiliarity, but produces no other hallucinogenic effects such as visuals, other perceptual effects, or euphoria. [6] [7] [1] [2] [3] [4] [5] However, the drug may produce more classically psychedelic effects at very high doses. [1] [8] It is taken orally, but can also be smoked. [1] [2] [3] [4] [5]

Contents

The drug acts as a serotonin receptor agonist, including of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors. [9] [10] [11] [12] [13] It has weak activity at the serotonin 5-HT1A receptor. [9] [10] DiPT does not appear to bind to the serotonin 5-HT6 receptor or to several other serotonin receptors. [13] It produces psychedelic-like effects in animals, which appear to be mediated primarily by serotonin 5-HT2A receptor activation. [9] [14] [12] The mechanisms by which DiPT produces selective auditory changes are unknown. [7] [1] [15] Derivatives of DiPT include 4-HO-DiPT (iprocin) and 5-MeO-DiPT (foxy methoxy), among others. [1]

DiPT was first described in the scientific literature by 1959. [16] The basic properties of DiPT in humans were described by Alexander Shulgin in 1976 [17] and its effects were described in detail by Shulgin in subsequent publications in the 1980s [18] [2] [19] [3] and in his 1997 book TiHKAL (Tryptamines I Have Known and Loved). [1] DiPT was encountered as a novel designer drug in 2005. [20] However, it appears to be little-used recreationally compared to other psychedelic drugs, perhaps due to its unusual effects. [18] [7]

Use and effects

In his book TiHKAL (Tryptamines I Have Known and Loved) and other publications, Alexander Shulgin lists DiPT's dose range as 25 to 100 mg orally and its duration as 6 to 8 hours. [1] In other publications however, he variably gives an effective dose range of 20 to 50 mg orally, a dose range of 40 to 100 mg orally, and a listed dose of 80 mg orally, as well as a shorter duration of 4 hours at lower doses and 5 hours at a higher dose. [2] [3] [4] [5] Per Shulgin, the full spectrum of effects of DiPT occur at a dose of 50 mg, while a dose of 80 mg has the same activity as a 50 mg dose and only results in an intensification of these effects. [2] [3] A wider recreational dose range for DiPT of 15 to 150 mg or more orally has also been reported, with a typical dose estimate of about 50 mg. [21] According to Shulgin, testing of DiPT started at a dose of 0.5 mg and gradually titrated up in 9 human volunteers, with threshold effects occurring at a dose of 16 mg orally. [2] There was also a report of 250 mg orally in TiHKAL, with apparently very strong effects. [1] The onset of DiPT is 20 to 30 minutes or up to 1 hour, peak effects occur after 1.5 to 2 hours, and full effects last for 1 to 2 hours. [1] [2] [3] In addition to oral administration, TiHKAL included a report of 8 mg DiPT smoked, with an onset of 4 to 8 minutes and a plus-two rating on the Shulgin Rating Scale. [1]

In major contrast to most other known serotonergic psychedelics, which are primarily visual in their effects, the effects of DiPT are unusual in that they are primarily or exclusively auditory. [6] [1] [2] [19] [3] [22] It is said to produce remarkable and extraordinary changes to sound perception, for instance of voices and music. [6] [1] [2] [3] DiPT reduces the perceived pitch (frequency) of sounds, causing an unusual tonal shift of all frequencies to a lower pitch. [6] [7] [1] [2] [3] It also causes distortion of pitch as well as of the timbre (tone quality) of sounds. [1] [2] [19] [3] As an example of its effects on pitch, DiPT makes peoples' voices sound much lower or deeper, like womens' voices being heard in bass tones or peoples' voices sound as if they have a bad cold. [6] [1] [2] [3] Voices are said to sound very similar to a single side-band radio signal being mistuned to the low side of the center frequency. [1] Despite these changes however, there were no effects on clarity of speech, and speech comprehension and interpretation were described as normal. [1]

DiPT makes music sound out of key and completely disharmonious, for instance piano playing sounding like a "bar-room disaster". [1] [3] However, single tones were said to sound normal aside from pitch changes. [1] DiPT does not cause a simple, linear, or proportional decrease in pitch, but decreases pitch by a fixed value. [1] [3] As a result, proportionality is lost, in turn resulting in complete harmonic distortion, jarring distortions of harmonic intervals, and music feeling qualitatively "wrong". [6] [1] [2] [3] An analogy given for this was someone having their thumb on an LP record and making everything come out at a 50 to 75% speed. [1] In terms of other sounds, telephone ringing sounds "partly underwater" with DiPT. [1] The drug causes abrupt sounds to have "golden spikes" attached to them as "after-sounds". [1] DiPT was reported to cause all familiar sounds to become foreign, even the mere chewing of food. [1] Sounds are said to be perceived as amplified or more intense and there is said to be a decrease in high-frequency acuity. [1] [19] The auditory and harmonic distortion with DiPT is described as intense or extreme, even at relatively low doses like 40 mg orally. [1] [5] There is said to be variability between individuals in terms of the auditory effects of DiPT. [2] [3]

Shulgin felt that DiPT could potentially be a useful tool in scientific research on the auditory system. [6] [7] [1] [19] He speculated that it might be able to help locate the pitch center of the brain, for instance if used in positron emission tomography (PET) imaging. [1] A small study involving DiPT administered to two people with perfect pitch was conducted and findings shared with Shulgin. [6] [1] It assessed whether there was some relationship between a note's pitch and the perceived pitch of the note. [1] No meaningful relationship was found, except reinforcement of the notion that the pitch decrease with DiPT is not linear and that there is true distortion instead of a simple pitch drop. [1] Interestingly, the plot of the error for each note against elapsed time provided an almost-quantitative measurement of DiPT's intensity and time-course of effects. [1] In the same study, pre-treatment with low doses of MDMA resulted in exaggeration of auditory distortion with DiPT, including an enhanced sound intensity that verged on being painful. [1] Aside from research on the auditory system, there has also been interest in DiPT in the study of music and language processing. [6]

In terms of its psychedelic-type effects, DiPT is said to produce only auditory changes. [6] [7] [3] One report observed auditory changes but no effects whatsoever in a quiet environment. [1] The subject remarked that if they were deaf, they would have assumed that DiPT was an inactive compound. [1] The drug is specifically said to produce no visual changes at all [5] or that visual effects with it are non-existent. [3] Relatedly, there was no visual distortion with DiPT at any time and there was no closed-eye imagery. [2] The drug is said to lack the intense sensory disturbances or hallucinogenic effects characteristic of other psychedelics like dimethyltryptamine (DMT) and psilocybin. [6] [2] Relatedly, DiPT produces no changes in vision, taste, or smell. [6] [1] Additionally, it is said to produce little to no euphoria. [2] [3] Moreover, its experience was described as passive and neutral rather than as pleasant or unpleasant, or that it had a somewhat neutral–negative response. [2] [3] Because of its lack of classical psychedelic-like effects, some authors have gone so far as to conclude that DiPT "distorts auditory perception and does not produce psychedelic effects". [8] Aside from hallucinogenic-related effects, DiPT is said to produce lethargy and a desire to lie down and remain that way, which are particularly prominent during the peak. [2] It is also reported to cause distance between oneself and one's surroundings and/or feelings, with these effects neither being disturbing nor stimulating. [2] Owing to its selective auditory effects, the outcomes of DiPT experiences may be less dependent on set and setting than those of other psychedelics. [6]

The drug is said to be relatively free of autonomic side effects and toxicity indications. [2] There are no changes in vital signs or motor coordination, although it was reported to cause handwriting impairment. [1] It causes slight ear pressure as if the eustachian tubes are clogged. [1] DiPT is also anecdotally claimed to produce tinnitus as a side effect. [23] In addition, it causes mild diarrhea, mild nausea, muscular hyperreflexia, and slight pupil dilation. [1] [2] [3] There were no changes in appetite and no sleep disruption. [1] [2]

Although DiPT produces selective auditory effects at typical doses, it appears to produce effects more similar to those of classical serotonergic psychedelics like LSD at higher doses. [1] [8] For example, in one report in TiHKAL that employed DiPT at a very high dose of 250 mg orally, the person described being spoken to and reassured by a "spirit", a feeling of foreboding, that "the light was there" but that DiPT was the "body of Satan", that they felt like they had been sent to an "anti-universe" where everything looked the same as normal but was a cold and empty imitation, and that they felt like a "fallen angel". [1] In addition to these effects, the person reported very strong auditory effects, such as mens' voices sounding like frogs and children sounding like they were speaking through synthesizers to imitate outer-space people in science-fiction movies. [1] While DiPT may be able to produce more classically psychedelic effects at high doses, the precise effective dose range for these effects is not well-defined. [8]

Other tryptamines reported to cause DiPT-esque sound distortion have included 2-methyl-DMT, 2-methyl-DET, and 5-MeO-DiPT. [1] Conversely, auditory changes or distortions with other psychedelics, including DMT, diethyltryptamine (DET), and ethylisopropyltryptamine (EiPT) among many others, are described as mild, rare, or absent. [1] [2] Similarly, auditory changes were not mentioned with methylisopropyltryptamine (MiPT) or 5-MeO-MiPT, except that these drugs produced enhanced auditory acuity and sound discrimination. [1] Although both DiPT and 5-MeO-DiPT can produce notable changes in auditory perception, DiPT's effects in general are said to differ from those of 5-MeO-DiPT's in most respects. [2] Moreover, 5-MeO-DiPT was reported to cause "some" musical sound distortion, specifically in terms of musical character and interpretation, but there were no apparent changes to harmonic structure in contrast to DiPT. [1] Shulgin speculated that 2-methyl-DiPT could be an interesting compound in terms of attempting to develop another psychedelic specifically affecting the auditory system, but he did not synthesize or test it. [1]

Interactions

Pharmacology

Pharmacodynamics

DiPT activities
Target Affinity (Ki, nM)
5-HT1A 121–2,270 (Ki)
4,570–>10,000 (EC50 Tooltip half-maximal effective concentration)
58% (Emax Tooltip maximal efficacy)
5-HT1B >10,000
5-HT1D 3,742
5-HT1E >10,000
5-HT1F ND
5-HT2A 1,200–>10,000 (Ki)
34–>10,000 (EC50)
81–117% (Emax)
5-HT2B 399 (Ki)
1,000–2,380 (EC50)
103–107% (Emax)
5-HT2C 290–>10,000 (Ki)
167–1,999 (EC50)
81–143% (Emax)
5-HT3 >10,000
5-HT4 ND
5-HT5A >10,000
5-HT6 >10,000
5-HT7 3,423
α1A, α1B >10,000
α1D ND
α2A 3,600–>10,000
α2B 2,870
α2C 2,523
β1, β2 >10,000
β3 ND
D1, D2 >25,000
D3 3,321–>25,000
D4, D5 >10,000
H1 920–3,583
H2 >10,000
H3 ND
H4 >10,000
M1M5 >10,000
I1 356
σ1 1,798
σ2 2,702
TAAR1 Tooltip Trace amine-associated receptor 1>15,000 (Ki) (mouse)
>15,000 (Ki) (rat)
ND (EC50) (mouse)
ND (EC50) (rat)
ND (EC50) (human)
ND (Emax) (mouse)
ND (Emax) (rat)
SERT Tooltip Serotonin transporter180–1,258 (Ki)
215–900 (IC50 Tooltip half-maximal inhibitory concentration)
IA (EC50)
NET Tooltip Norepinephrine transporter8,900–>10,000 (Ki)
9,900–>10,000 (IC50)
IA (EC50)
DAT Tooltip Dopamine transporter4,100–>10,000 (Ki)
4,788–35,000 (IC50)
IA (EC50)
Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified. Refs: [24] [13] [9] [10] [11] [12] [25]

DiPT binds to serotonin receptors including the serotonin 5-HT1A, 5-HT2A, 5-HT2B, 5-HT2C receptors among others. [13] [11] It is known to act as a full agonist of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors. [13] [11] The drug has weak activity at the serotonin 5-HT1A receptor. [9] [10] It is also a weak serotonin reuptake inhibitor. [11] In contrast to many related drugs, DiPT does not interact with the rodent or human trace amine-associated receptor 1 (TAAR1). [25]

DiPT fully substitutes for dimethyltryptamine (DMT) and DOM and partially substitutes for LSD in rodent drug discrimination tests. [9] [8] Conversely, it does not substitute for cocaine, methamphetamine, or MDMA. [9] When DiPT is used as the training drug, LSD, DOM, and MDMA fully substitute for DiPT while DMT only partially substitutes for DiPT and methamphetamine fails to substitute. [26] Its stimulus properties in drug discrimination tests are partially blocked by the serotonin 5-HT2A receptor antagonist volinanserin and by the serotonin 5-HT2C receptor antagonist SB-242084. [14] [12] This is in contrast to the case of the related psychedelic DMT, wherein volinanserin fully blocks its stimulus properties and SB-242084 has minimal influence. [14] [12] Nonetheless, it was concluded that the serotonin 5-HT2A receptor primarily mediates the interoceptive effects of DiPT in rodents. [14] [12] Besides serotonin receptors, the metabotropic glutamate mGlu2 and mGlu3 receptor agonist LY-379268 had minimal effects on the stimulus properties of DiPT, whereas the mGlu2 and mGlu3 receptor antagonist LY-341495 potentiated DiPT discrimination. [14] [12]

Similarly to DMT and other psychedelics, DiPT produces the head-twitch response, a behavioral proxy of psychedelic-like effects, in rodents, and this effect is blocked by volinanserin. [12] [8] In addition, DiPT produces hypolocomotion. [9] The drug also produces convulsions at high doses in rodents. [9]

The unique auditory effects of DiPT in humans have not yet been properly evaluated or demonstrated in animals. [7]

Chemistry

DiPT, also known as N,N-diisopropyltryptamine, is a derivative of tryptamine formed by substituting isopropyl groups for the two hydrogen atoms attached to the non-aromatic nitrogen atom in the tryptamine molecule. [1]

Synthesis

The chemical synthesis of DiPT has been described. [1] [2]

Analogues

Analogues of DiPT include dimethyltryptamine (DMT), diethyltryptamine (DET), dipropyltryptamine (DPT), diallyltryptamine (DALT), 5-MeO-DiPT, 4-HO-DiPT (iprocin), 5-HO-DiPT, 4-AcO-DiPT (ipracetin), 5,6-MDO-DiPT, methylisopropyltryptamine (MiPT), ethylisopropyltryptamine (EiPT), and propylisopropyltryptamine (PiPT), among others. [1]

2-Methyl-DiPT

2-Methyl-DiPT, the 2-methyl derivative of DiPT, was mentioned by Alexander Shulgin in his book TiHKAL (Tryptamines I Have Known and Loved) as a potentially interesting analogue of DiPT that might likewise produce selective auditory effects. [1] This was based on findings that other 2-methylated tryptamines like 2-methyl-DMT and 2-methyl-DET have also uniquely been found to produce DiPT-like auditory effects. [1] However, 2-methyl-DiPT is not known to have been synthesized or tested. [1]

History

DiPT was first described in the scientific literature by R. B. Barlow and colleagues by 1959. [16] Alexander Shulgin disclosed the basic properties of DiPT in humans in 1976 based on unpublished findings of his cited to 1974. [17] [27] Subsequently, Shulgin described DiPT, along with 5-MeO-DiPT, in much greater detail in a 1980 journal article. [2] He also described it in further detail in other articles published in the 1980s, [18] [19] [3] as well as in his 1997 book TiHKAL (Tryptamines I Have Known and Loved). [1] DiPT was encountered as a novel designer drug in Europe in 2005. [20] However, DiPT appears to be relatively little used recreationally compared to other psychedelic drugs. [18] This may be related to its unusual effects, including lacking the typical recreational effects associated with psychedelic drugs. [7]

Society and culture

United Kingdom

As is the case with many psychedelic tryptamines and phenethylamines, it is Class A in the UK, making it illegal to possess or use.

United States

DiPT is not scheduled at the federal level in the United States, [28] but it could be considered an analog of 5-MeO-DiPT, in which case purchase, sale, or possession for human consumption or illicit use that is not for scientific or industrial purposes could be prosecuted under the Federal Analog Act. Some of the people arrested in Operation Web Tryp were selling DiPT, however the drug is not explicitly forbidden or outlawed.

However the US Drug Enforcement Agency (DEA) withdrew a proposal to ban five psychedelic substances including 4-Hydroxy-N,N-diisopropyltryptamine (4-OH-DiPT), N-Isopropyl-5-Methoxy-N-Methyltryptamine (5-MeO-MiPT) and N,N-Diisopropyltryptamine (DiPT). DEA withdrew the proposed listing as schedule 1 banned substance after a public hearing in 2022. [29]

Florida

"DiPT (N,N-Diisopropyltryptamine)" is a Schedule I controlled substance in the state of Florida making it illegal to buy, sell, or possess in Florida. [30]

Sweden

Sweden's public health agency suggested classifying DiPT as a hazardous substance, on May 15, 2019. [31]

See also

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 Shulgin A (1997). TiHKAL: Tryptamines I Have Known and Loved. Berkeley, CA USA: Transform Press. pp. 403–406. ISBN   978-0-9630096-9-2.
  2. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 Shulgin AT, Carter MF (1980). "N, N-Diisopropyltryptamine (DIPT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT). Two orally active tryptamine analogs with CNS activity". Communications in Psychopharmacology. 4 (5): 363–369. PMID   6949674. Archived from the original on 2025-07-12.
  3. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 Shulgin AT (January 1988). "DIPT: The Distortion of Music". High Frontiers/Reality Hackers. 6: 27. Archived from the original on 2025-07-13.
  4. 1 2 3 4 Jacob P, Shulgin AT (1994). "Structure-Activity Relationships of the Classic Hallucinogens and Their Analogs". In Lin GC, Glennon RA (eds.). Hallucinogens: An Update (PDF). National Institute on Drug Abuse Research Monograph Series. Vol. 146. National Institute on Drug Abuse. pp. 74–91. PMID   8742795. Archived from the original on 13 July 2025.
  5. 1 2 3 4 5 6 Shulgin AT (2003). "Basic Pharmacology and Effects". In Laing RR (ed.). Hallucinogens: A Forensic Drug Handbook. Forensic Drug Handbook Series. Elsevier Science. pp. 67–137. ISBN   978-0-12-433951-4. Archived from the original on 13 July 2025.
  6. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Corey V, Halpern JH, Passie T (2012). "Psychoactive Substances". Hallucinations. New York, NY: Springer New York. pp. 297–316. doi:10.1007/978-1-4614-0959-5_22. ISBN   978-1-4614-0958-8 . Retrieved 9 November 2025. 22.2.3.2 DiPT A member of the tryptamine chemical family, diisopropyltryptamine (DiPT) is a fascinating substance because, unlike most hallucinogens, its effects are predominantly auditory. It is also possibly less sensitive than other hallucinogens to the mindset of the user, the setting in which it is ingested, and other psychological considerations, perhaps because the auditory system has become less salient to the human organism as we have evolved into a vision-based species. In general, auditory pitch is perceived as lower than normal, and harmonious sounds lose their resonance with one another. This dissonance is even perceived by people with perfect pitch, which has some implications about where in the processing stream DiPT's effects occur. Voices are also altered and disharmonious with one another (Shulgin and Shulgin 1997 ) . DiPT has few other known effects; it would seem to call for further investigation from those interested in the neurology of sound, music, and verbal language processing. For example, it would be fascinating to know the effects of this substance on perceptions of tonal languages such as Chinese, Huichol, or Dogon; would it alter the words perceived as being spoken?
  7. 1 2 3 4 5 6 7 8 Hamlet WR (2010). The effect of N, N-Diisopropyltryptamine on modified acoustic startle reflex tasks (Master of Science thesis). Western Illinois University.
  8. 1 2 3 4 5 6 Halberstadt AL, Chatha M, Klein AK, Wallach J, Brandt SD (May 2020). "Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species". Neuropharmacology. 167 107933. doi:10.1016/j.neuropharm.2019.107933. PMC   9191653 . PMID   31917152.
  9. 1 2 3 4 5 6 7 8 9 Gatch MB, Forster MJ, Janowsky A, Eshleman AJ (July 2011). "Abuse liability profile of three substituted tryptamines". The Journal of Pharmacology and Experimental Therapeutics. 338 (1): 280–289. doi:10.1124/jpet.111.179705. PMC   3126641 . PMID   21474568.
  10. 1 2 3 4 Blough BE, Landavazo A, Decker AM, Partilla JS, Baumann MH, Rothman RB (October 2014). "Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes". Psychopharmacology. 231 (21): 4135–4144. doi:10.1007/s00213-014-3557-7. PMID   24800892.
  11. 1 2 3 4 5 Rickli A, Moning OD, Hoener MC, Liechti ME (August 2016). "Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens". European Neuropsychopharmacology. 26 (8): 1327–1337. doi:10.1016/j.euroneuro.2016.05.001. PMID   27216487. S2CID   6685927.
  12. 1 2 3 4 5 6 7 8 Carbonaro TM, Eshleman AJ, Forster MJ, Cheng K, Rice KC, Gatch MB (January 2015). "The role of 5-HT2A, 5-HT 2C and mGlu2 receptors in the behavioral effects of tryptamine hallucinogens N,N-dimethyltryptamine and N,N-diisopropyltryptamine in rats and mice". Psychopharmacology. 232 (1): 275–284. doi:10.1007/s00213-014-3658-3. PMC   4282596 . PMID   24985890. DiPT bound with moderate affinity to the 5-HT2C receptor (Ki= 290 ± 110 nM; Hill coefficient = −0.72 ± 0.05) and was a full agonist in the IP-1 formation assay (EC50 = 2380 ± 340 nM), producing 107.4 ± 2.5% of the maximal 5-HT effect.
  13. 1 2 3 4 5 Ray TS (February 2010). "Psychedelics and the human receptorome". PloS One. 5 (2) e9019. Bibcode:2010PLoSO...5.9019R. doi: 10.1371/journal.pone.0009019 . PMC   2814854 . PMID   20126400.
  14. 1 2 3 4 5 Baker LE (2018). "Hallucinogens in Drug Discrimination". Current Topics in Behavioral Neurosciences. 36: 201–219. doi:10.1007/7854_2017_476. PMID   28484970.
  15. Ballentine G, Friedman SF, Bzdok D (March 2022). "Trips and neurotransmitters: Discovering principled patterns across 6850 hallucinogenic experiences". Science Advances. 8 (11) abl6989. doi:10.1126/sciadv.abl6989. PMID   35294242.
  16. 1 2 Barlow RB, Khan I (March 1959). "Actions of some analogues of tryptamine on the isolated rat uterus and on the isolated rat fundus strip preparations". British Journal of Pharmacology and Chemotherapy. 14 (1): 99–107. doi:10.1111/j.1476-5381.1959.tb00934.x. PMC   1481812 . PMID   13651585.
  17. 1 2 Shulgin AT (1976). "Psychotomimetic Agents". Psychopharmacological Agents. Elsevier. pp. 59–146. doi:10.1016/b978-0-12-290559-9.50011-9. ISBN   978-0-12-290559-9 . Retrieved 9 November 2025. [5-MeO-DMT] has been shown to be a centrally active drug in animal studies (Gessner and Page, 1962; Gallagher et al., 1964) and to be active parenterally in man. Like [DMT], it is not active orally, although the N,N-diisopropyl homolog [(DiPT)], as with the hindered dialkyl tryptamines mentioned earlier, is effective by the oral route (A. T. Shulgin, unpublished data, 1974). [...] With this in mind, three comments should be made. It is "knowledge" within the anonymous underground drug publications that not only is the [DPT] homolog mentioned above active orally but also that the diisopropyl counterpart [(DiPT)] is especially so.
  18. 1 2 3 4 Zamberlan F, Sanz C, Martínez Vivot R, Pallavicini C, Erowid F, Erowid E, et al. (8 November 2018). "The Varieties of the Psychedelic Experience: A Preliminary Study of the Association Between the Reported Subjective Effects and the Binding Affinity Profiles of Substituted Phenethylamines and Tryptamines". Frontiers in Integrative Neuroscience. 12 54. doi: 10.3389/fnint.2018.00054 . PMID   30467466. A large body of anecdotal experiences supports the existence of differences in the subjective effects of serotonergic psychedelics, in particular concerning those elicited by relatively novel synthetic derivatives of phenethylamines (i.e., mescaline analogs) and tryptamines (i.e., DMT analogs). A frequently cited example is that of N,N-Diisopropyltryptamine (DiPT), a substituted tryptamine and 5-HT1A/2A agonist remarkable for producing auditory distortions, in contrast to the predominantly visual effects of classic psychedelics (Shulgin and Carter, 1979; Shulgin and Shulgin, 1997; Kometer and Vollenweider, 2016). [...] • DiPT (N,N-Diisopropyltryptamine): substituted tryptamine, first synthesized and tested by Shulgin and Carter (1979). [...] A total of 16 reports were obtained for mescaline, 143 for 2C-B, 206 for 2C-E, 101 for 2C-T-2, 36 for DOB, 32 for DOI, 23 for DOM, 19 for TMA-2, 63 for MDA, 770 for MDMA, 236 for DMT, 247 for 5-MeO-DMT, 69 for 5-MeO-MiPT, 45 for DiPT, 182 for 5-MeO-DiPT, 137 for DPT, 718 for LSD, 32 for ibogaine, 64 for 2C-C, 383 for 2C-I, 57 for 2C-P, 16 for 2C-T-4, 171 for 2C-T-7, 48 for 2C-D, 144 for 25I-NBOMe, 51 for 4-OH-MET, 109 for 5-MeO-AMT, 208 for 4-OH-DiPT and 8 for psilocin/psilocybin.
  19. 1 2 3 4 5 6 Shulgin AT, Shulgin LA, Jacob P (May 1986). "A protocol for the evaluation of new psychoactive drugs in man". Methods and Findings in Experimental and Clinical Pharmacology. 8 (5): 313–320. PMID   3724306. Archived from the original on 2025-07-12. Sensory amplification: A deceptively simple tryptamine DIPT (N,N-diisopr()pyltryptamine) has been reported to amplify and distort the auditory sensory input signals (2) in preference to the more frequently seen visual distortions. This modality is closer to the usual symptomology of endogenous schizophrenia, and may well serve as a discriminating tool for differential research.
  20. 1 2 EMCDDA–Europol. "Annual Report on the implementation of Council Decision". 2005/387/JHA.
  21. Luethi D, Liechti ME (October 2018). "Monoamine Transporter and Receptor Interaction Profiles in Vitro Predict Reported Human Doses of Novel Psychoactive Stimulants and Psychedelics". The International Journal of Neuropsychopharmacology. 21 (10): 926–931. doi:10.1093/ijnp/pyy047. PMC   6165951 . PMID   29850881.
  22. Larøi F, Sommer IE, Blom JD, Fernyhough C, Ffytche DH, Hugdahl K, et al. (June 2012). "The characteristic features of auditory verbal hallucinations in clinical and nonclinical groups: state-of-the-art overview and future directions". Schizophrenia Bulletin. 38 (4): 724–733. doi:10.1093/schbul/sbs061. PMC   3406519 . PMID   22499783. Auditory hallucinations can sometimes be triggered by the use of—or withdrawal from—illicit substances such as alcohol, cannabis, amphetamines, cocaine, [LSD], and [DMT]. Generally speaking, hallucinogens are more likely to induce visual than auditory misperceptions. If auditory misperceptions occur at all, they tend to do so in the context of compound hallucinations. A notable exception is diisopropyltryptamine (DiPT), a hallucinogenic of the tryptamine family, which primarily affects auditory pitch.
  23. Hill SL, Thomas SH (October 2011). "Clinical toxicology of newer recreational drugs". Clinical Toxicology. 49 (8): 705–719. doi:10.3109/15563650.2011.615318. PMID   21970769. Other unsubstituted simple synthetic tryptamines are N,N-diallyltryptamine (DALT), diethyltryptamine (DET), di-isopropyltryptamine (DiPT) and dipropyltryptamine (DPT) (see Fig. 5). Each is active after ingestion, with serotonin-mediated visual hallucinations the main clinical effect. DiPT is unusual in that it produces primarily auditory hallucinations, with tinnitus as a side effect. 154
  24. "Kᵢ Database". PDSP. 25 March 2025. Retrieved 25 March 2025.
  25. 1 2 Simmler LD, Buchy D, Chaboz S, Hoener MC, Liechti ME (April 2016). "In Vitro Characterization of Psychoactive Substances at Rat, Mouse, and Human Trace Amine-Associated Receptor 1" (PDF). The Journal of Pharmacology and Experimental Therapeutics. 357 (1): 134–144. doi:10.1124/jpet.115.229765. PMID   26791601. Archived from the original (PDF) on 9 May 2025.
  26. Carbonaro TM, Forster MJ, Gatch MB (March 2013). "Discriminative stimulus effects of N,N-diisopropyltryptamine". Psychopharmacology. 226 (2): 241–246. doi:10.1007/s00213-012-2891-x. PMID   23070023.
  27. "DIPT" (PDF). pihkal.
  28. "21 CFR — SCHEDULES OF CONTROLLED SUBSTANCES §1308.11 Schedule I." Drug Enforcement Administration (DEA). U.S. Department Of Justice. Archived from the original on 2009-08-27. Retrieved 2014-12-17.
  29. "Placement of 4-hydroxy-N,N-diisopropyltryptamine (4-OH-DiPT), 5-methoxy-alpha-methyltryptamine (5-MeO-AMT), 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT), 5-methoxy-N,N-diethyltryptamine (5-MeO-DET), and N,N-diisopropyltryptamine (DiPT) in Schedule I; Withdrawal of Proposed Rule". 27 July 2022.
  30. "Chapter 893 - Drug Abuse Prevention and Control". Florida Statutes.
  31. "Folkhälsomyndigheten föreslår att 20 ämnen klassas som narkotika eller hälsofarlig vara" (in Swedish). Folkhälsomyndigheten. 15 May 2019. Archived from the original on 20 October 2021. Retrieved 11 November 2019.